Tonix Pharmaceuticals Holding Corp.
TNXP
NASDAQ·Healthcare·Biotechnology·Mkt cap $209.5M
$13.14
▼ -1.72%
P/E
-1.61
Mkt Cap
$209.5M
52-Wk Range
$9.40–$31.55
52-Week Range
$9.40 - $31.55
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 48.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary recombinant pox vaccine (RPV) platform enabling rapid vaccine development
- Diversified pipeline reducing development risk across multiple therapeutic areas and indications
- TNX-102 SL dual-indication potential (fibromyalgia and Long COVID) maximizing asset value
- Strategic focus on high-unmet-need markets with limited competitive alternatives
- Combination of small molecule and biologic development capabilities
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Strong growth ahead
Strong revenue growth (30% YoY)
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+12.2% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying TNXP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$2.44 vs -$2.64 consensus (+7.6% surprise). Revenue of $13.5M vs $7.7M expected (+75.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+7.6%
Revenue trend · last 8Q
—
-32%
-2%
-10%
+17%
+109%
+183%
+578%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.8M
$2.6M
$2.4M
$2.0M
$3.3M
$5.4M
$6.9M
$13.5M
Margins · last 8Q
Gross
98.9%
Profit
296.8%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Raymond James · Aug 10, 2026
vs Industry
How TNXP stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related